| 000 | 01218 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250516033745.0 | ||
| 264 | 0 | _c20110914 | |
| 008 | 201109s 0 0 fre d | ||
| 022 | _a2213-3941 | ||
| 024 | 7 |
_a10.1016/j.ando.2011.03.020 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchlumberger, M | |
| 245 | 0 | 0 |
_a[Management of refractory thyroid cancers]. _h[electronic resource] |
| 260 |
_bAnnales d'endocrinologie _cApr 2011 |
||
| 300 |
_a149-57 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aCarcinoma, Papillary |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aThyroid Cancer, Papillary |
| 650 | 0 | 4 |
_aThyroid Neoplasms _xdrug therapy |
| 773 | 0 |
_tAnnales d'endocrinologie _gvol. 72 _gno. 2 _gp. 149-57 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ando.2011.03.020 _zAvailable from publisher's website |
| 999 |
_c20779669 _d20779669 |
||